229 related articles for article (PubMed ID: 16321854)
1. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.
Schöllkopf C; Kjeldsen L; Bjerrum OW; Mourits-Andersen HT; Nielsen JL; Christensen BE; Jensen BA; Pedersen BB; Taaning EB; Klausen TW; Birgens H
Leuk Lymphoma; 2006 Feb; 47(2):253-60. PubMed ID: 16321854
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
Kotani T; Takeuchi T; Kawasaki Y; Hirano S; Tabushi Y; Kagitani M; Makino S; Hanafusa T
Lupus; 2006; 15(10):683-5. PubMed ID: 17120596
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.
Vassou A; Alymara V; Chaidos A; Bourantas KL
Int J Hematol; 2005 Jun; 81(5):421-3. PubMed ID: 16158824
[TBL] [Abstract][Full Text] [Related]
4. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Peñalver FJ; Alvarez-Larrán A; Díez-Martin JL; Gallur L; Jarque I; Caballero D; Díaz-Mediavilla J; Bustelos R; Fernández-Aceñero MJ; Cabrera JR;
Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
6. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.
Berentsen S; Tjønnfjord GE; Brudevold R; Gjertsen BT; Langholm R; Løkkevik E; Sørbø JH; Ulvestad E
Br J Haematol; 2001 Oct; 115(1):79-83. PubMed ID: 11722415
[TBL] [Abstract][Full Text] [Related]
7. [Delayed response to rituximab of cold agglutinin haemolytic disease].
Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma.
Cohen Y; Polliack A; Zelig O; Goldfarb A
Leuk Lymphoma; 2001; 42(6):1405-8. PubMed ID: 11911426
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.
Tanaka H; Hashimoto S; Sugita Y; Sakai S; Takeda Y; Abe D; Takagi T; Nakaseko C
Int J Hematol; 2012 Oct; 96(4):501-5. PubMed ID: 22878940
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.
Berentsen S; Ulvestad E; Gjertsen BT; Hjorth-Hansen H; Langholm R; Knutsen H; Ghanima W; Shammas FV; Tjønnfjord GE
Blood; 2004 Apr; 103(8):2925-8. PubMed ID: 15070665
[TBL] [Abstract][Full Text] [Related]
12. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Maung SW; Leahy M; O'Leary HM; Khan I; Cahill MR; Gilligan O; Murphy P; McPherson S; Jackson F; Ryan M; Hennessy B; McHugh J; Goodyer M; Bacon L; O'Gorman P; Nee A; O'Dwyer M; Enright H; Saunders J; O'Keeffe D
Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468
[TBL] [Abstract][Full Text] [Related]
13. [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
[TBL] [Abstract][Full Text] [Related]
14. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
[TBL] [Abstract][Full Text] [Related]
15. Remission of severe cold agglutinin disease after Rituximab therapy.
Layios N; Van Den Neste E; Jost E; Deneys V; Scheiff JM; Ferrant A
Leukemia; 2001 Jan; 15(1):187-8. PubMed ID: 11243390
[No Abstract] [Full Text] [Related]
16. [Rituximab in cold agglutinin disease].
Camou F; Viallard JF; Pellegrin JL
Rev Med Interne; 2003 Aug; 24(8):501-4. PubMed ID: 12888170
[TBL] [Abstract][Full Text] [Related]
17. [Efficacity of rituximab in hemolytic anemia with cold autoantibodies case].
Sekkach Y; Hammi S; Elqatni M; Fatihi J; Elomri N; Mekouar F; Badaoui M; Jira M; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Jul; 69(4):205-8. PubMed ID: 21840439
[TBL] [Abstract][Full Text] [Related]
18. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
Eriksson P
J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
20. Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease.
Brauer DL; Edelman B; Rapoport AP; Hess JR; Akpek G
Transfusion; 2012 Nov; 52(11):2432-5. PubMed ID: 22435421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
